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Abstract
Background: Chronic lymphocytic leukemia (CLL) is a monoclonal disorder, characterized by a
progressive proliferation of functionally incompetent B lymphocytes. There is increased evidence
of association between CLL and skin cancers, including the uncommon Merkel cell carcinoma
(MCC).
Case presentation: A case report of an 84-year old male, who presented with an aggressively
recurrent form of MCC on the lower lip, on the background of an 8-year history of untreated CLL.
During the recurrences of MCC, coexisting regional lymphadenopathy, posed a problem in the
differential diagnosis and treatment of lymph node involvement. Histopathology and
immunoistochemistry showed that submandibular lymphadenopathy coexisting with the second
recurrence of MCC, was due to B-cell small lymphocytic lymphoma. The subsequent and more
aggressive recurrence of the skin tumor had involved the superficial and deep cervical lymph nodes.
Surgical excision followed by involved field radiation therapy has been proven effective for both
malignancies.
Conclusion: MCC has a high incidence of regional lymphadenopathy at presentation (12–45%) and
even when it arises on the background of chronic leucemia, lymphadenopathy at presentation
should be managed agressively with elective lymph node dissection. We overview the postulated
correlation between Merkel tumor and CCL, the differential diagnosis of regional lymphadenopathy
during the recurrences of the skin tumor and the strategies of treatment
Background
MCC, is an uncommon tumor, which mostly occurs as an
asymptomatic, solitary, firm and red-pink nodule. It has
been linked to increased sun exposure [1], both in its ana-
tomic and geographical distribution. Usually is nonulcer-
ated and ranges from 0.8 to 4 cm in diameter [2,3].
Predominantly involves the head and neck region (65%)
[4,5], followed by the upper extremities (18%), and the
lower extremities (13%) [3]. The precice origin is still con-
troversial. However, the Merkel cell (assumed to be a
touch receptor) and the melanocyte are the cutaneous
counterparts of the Amine Precurcor Uptake and
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Decarboxylation (APUD) cells, which are of neuroecto-
dermal origin [6,7].
The tumor is composed of small blue cells with hyper-
chromatic nuclei and minimal cytoplasm. Mitoses,
nuclear fragments and lymphovascular invasion are
almost invariable features [8]. Immunoistochemistry for
cytokeratin species more typical of simple epitelial cells
than keratinocytes, permits a differential identification of
Merkel cells in tissue sections [9]. The immunoistochem-
ical profile is characterized of positivity for Neuron-Spe-
cific Enolase (NSE), Neurofilament Protein (NFP) and
CD57- CD99 [10]. A single punctate zone of cytoplasmic
immunoreactivity for cytokeratins especially CK20 is
more characteristic [11]. The reaction for CK20 has been
used as a finding against metastatic small cell carcinoma
of the lung (Cytokeratin 7+ and Thyroid Transcription
Factor 1+), small cell melanoma (S100+) and lymphoma
(Leucocyte Common Antigen +) [12].
MCC appears to metastasize principally via the lymphat-
ics in a predictable stepwise fashion, with an initial
involvement of the regional lymph nodes and subsequent
systemic spread [13]. If the lymph nodes are not palpable,
the pathological examination of the primary tumor
(larger than 2 cm, high mitotic rate and lymphatic inva-
sion) serves as a parameter for the need of lymph node
biopsies [5]. Surgical excision with tumor free margins is
the primary therapy for stage I-localized disease, with a
64% of survival in 5 years. However recent studies have
shown that there is no clear evidence of a difference in sur-
vival [2,14], when the margins of resection are less than
the 2–3 cm as generally recommended [2,13]
In fact, Mohs micrographic surgery may be more effica-
cious than wide excision as it inspects all major borders,
including the deep margin (MCC often shows extensive
vertical growth) and also allows maximal sparing of nor-
mal additional tissue, especially in such cosmetically sen-
sitive anatomic areas as the face [15]. A useful adjunct in
the treatment of MCC is the sentinel node mapping,
which identifies the status of the first draining lymph
node and allows to avoid unnecessary lymphadenecto-
mies and the resulting postoperative morbidity [16].
MCC cells are radiosensitive, and several studies have
argued for the benefits of radiation therapy not only after
resection for local recurrence and palliation but as well as
adjuvant treatment after initial surgery with curative
intent [12]. Chemotherapy is the least studied theraupetic
component and propably is mandatory in unresectable or
unmanagable by radiotherapy tumors, as well as in meta-
static disease [8,17].
CLL occurs primarily in middle-aged and elderly individ-
uals, with increasing frequency in successive decades of
life. It involves slow proliferation and accumulation of
incompetent B-lymphocytes and concurrent abnormali-
ties in both humoral and cellular immunity. The majority
of patients live 5–10 years, with an initial course that is
relatively benign but followed by a terminal, progressive
and resistant fase lasting 1–2 years. During the later phase,
morbidity is considerable both from the disease and the
associated incidence of malignant neoplasms (especially
skin cancers as squamous cell carcinoma, Kaposi sarcoma
and melanoma) [19]. CLL shares a clinical and morpho-
logical overlap with Small Lymphocytic Lymphoma
(SLL). In fact if a patient has an absolute lymphocytosis of
> 5000/mm3 in the peripheral blood, CLL is diagnosed,
regardless of the findings in the lymph node [19].
Treatment of CCL ranges from periodic observation with
treatment of infectious, hemorrhagic or immunologic
complications to a variety of therapeutic options, includ-
ing steroids, alkylating agents, purine analogues, combi-
nation chemotherapy, monoclonal antibodies and
transplant options [20]. As it occurs in an elderly popula-
tion, progresses slowly and generally is not curable, it is
usually treated in a conservative fashion [21]. Involved-
field radiation therapy with relatively low doses of radia-
tion can effect an excellent response for both CLL and
Small Lymphocytic Lymphoma, especially when the lym-
phoma cells are contained in one or two areas of lymph
nodes in the same part of the body.
Case presentation
An 84-year old white male, presented at the Department
of Dermatology (6th IKA Oncological Hospital of Athens)
with a pale, ulcerated lesion (1.3 cm in diameter), on the
middle of his lower lip. There was no associated lymphad-
enopathy and an excisional biopsy was performed. His-
topathological and immunoistochemical features
revealed a Merkel cell carcinoma (MCC) but as the exci-
sion was incomplete the patient was sheduled for a wider
excision in the following 2 months. In the meantime, the
lesion recurred and the patient returned with a protruding
white lesion of 1.1 cm in diameter. There was no associ-
ated lynphadenopathy and a wider excision, with an 8
mm margin, was performed. Histopathology confirmed
the nature of MCC and the second excision was within
healthy margins.
Two months later, the patient was referred to the Depat-
ment of Plastic Surgery, for another protruding ulcerated
lesion, 3 cm in diameter, on his lower lip (Fig 1). On
examination, multiple palpable lymph nodes in the sub-
mandibular and cervical area (superficial and deep cervi-
cal lymphadenopathy) were present.BMC Cancer 2005, 5:106 http://www.biomedcentral.com/1471-2407/5/106
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Past medical history revealed that 8 years earlier, the
patient had been diagnosed as having chronic lym-
phocytic leukemia (CLL), (nodular and intermediate
type), but he didn't receive any treatment. CT scan of the
head and neck area, showed a soft tissue lobular mass, 3
cm in diameter, on the lower lip, with a possible exten-
sion to the mandible. The past medical history of CLL
with the recent occurence of MCC posed a problem in the
differential diagnosis of the patient's lymphadenopathy.
A W-excision (4 × 3.5 × 1 cm) of the lip lesion was per-
formed, with an open biopsy of one submandibular
lymph node.
Histopathology, confirmed recurrence of MCC. An undif-
ferentiated small cell carcinoma with hyaluronated
stroma was identified. The cells arranged in nodules or
rosettes, had dense nuclear chromatin, with mitoses and
nuclear debris which are regular features of MCC (Fig. 2,
3).
Immunoistochemical procedures showed Neuron Spe-
cific Enolase (NSE) positivity, while antibodies for Epithe-
lial Membrane Antigen (EMA) and Chromogranin were
negative. The excision was described as complete. The
submandibular lymph node was positive for malignacy
but was associated with the CLL (non Hodgkin's, B cell
small lymhocytic lymphoma). There was no evidence of
metastatic infiltration by MCC and this was confirmed
immunoistochemically with the positive expression of
CD5 and CD20 antibody and negative expression of
CD10 antibody and NSE. Due to the age of the patient,
chemotherapy was not considered.
A month later, a new CT scan of the head and neck,
depicted a soft tissue mass, consistent with recurrence of
MCC, between the left angle of the mandible and the
hyoid bone. Multiple enlarged superficial and deep cervi-
cal lymph nodes were present. Fine needle aspiration
(FNA) of the submandibular swelling was performed and
Clinical appearance of second recurrence of Merkel tumor on lower lip Figure 1
Clinical appearance of second recurrence of Merkel tumor on lower lip.BMC Cancer 2005, 5:106 http://www.biomedcentral.com/1471-2407/5/106
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confirmed MCC (small atypical cells were found, isolated
or forming rosettes and exhibited dense core granules of
chromatin and scanty cytoplasm). The patient underwent
one month of neck radiotherapy with Cobalt 60, a total
dose of 4600cGy in 23 days. A further boost of 600cGy in
2 days, on the left submandibular area was administered.
The treatment was successfully completed with full remis-
sion of the cervical lymphadenopathy. Two months fol-
lowing the radiotherapy, a new CT scan of the head and
neck showed reduction and obscurrence of the pre-exist-
ing mass on the left mandibular area, while the lymph
nodes were smaller too. The patient is on regular follow
up and CLL status is stable with no evidence of progres-
sion or further recurrence of MCC 9 months post-
radiotherapy.
Conclusion
Our patient represents another case of MCC arising on
CLL and this ocurrence re-inforces the postulated correla-
tion between these 2 malignancies. There are two main
aetiological factors associated with increased risk of skin
cancers: Ultraviolet radiation and immunosupression.
CLL is thought to cause immunosupression and alcylating
agents and other immunosuppressant therapies may be
involved [22]. A higher incidence of MCC is seen in
patients with organ transplantation, with human immun-
odeficiency virus-1 infection or with advanced cancer and
anergic status [23].
On the other side, CLL is relatively common and the asso-
ciation with skin cancers, including the rarer MCC, may
be coincidental [24]. The submandibular
Histopathology showing undifferentiated small cell carcinoma with paucicellular stroma and cells forming nodules or rosettes  (haematoxylin and eosin; × 100) Figure 2
Histopathology showing undifferentiated small cell carcinoma with paucicellular stroma and cells forming nodules or rosettes 
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lymphadenopathy on the second recurrence was unex-
pectedly due to lymphoma and this complicated the deci-
sion on the modality of treatment and further
management of the patient. Fortunately both tumors
responded to field radiation therapy and on the last fol-
low up there was no evidence of deterioration of the
leukemic status or MCC metastatic spread. Probably, a
wider excision during the initial diagnosis of the skin
tumor (with at least a 1.5 cm margin) [13], should have
led to an earlier regression of MCC. However, Gillenwater
et al [25] demonstrated no difference in outcome based
on margins < 1 cm, 1 to 2 cm and > 2 cm. On the other
sider, considering the agressiveness of MCC, radiation
therapy should have been involved during the second
recurrence, although lymphadenopathy was then positive
only for CLL related lymphoma. However, as the subse-
quent lymph node recurrence of MCC occurred only one
month later, it raises the possibility that it was already
present when the biopsy was performed and the biopsy
result was falsely reassuring.
Complete spontaneous regression constitutes 1.67% of
the approximately 600 reported cases of MCC[26]. There-
fore, MCC once recognized has to be treated agressively.
Studies have shown that the best outcome is obtained in
patients with regional disease following lymph node dis-
section with or without subsequent radiation. Our case
report highlights the importance of aggressive treatment
of MCC with elective lymph node dissection at presenta-
tion, even if the coexisting lymphadenopathy could be
related to the coexisting CLL
Certainly, on the background of CLL, clinicopathological
features and treatment modalities are more complicated
and effectiveness depends on the activity status of the
leukemia, which could facilitate recurrence and regional
or distant metastatic spread.
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Histopathology showing Merkel cells arranged in rosettes with mitoses present (haematoxylin eosin; × 100) Figure 3
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